These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30406424)

  • 1. BRAF mutation testing in melanoma: results from a German observational multicenter study.
    Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
    Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
    Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
    Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
    Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
    Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
    Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
    Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
    Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
    Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.
    Gaiser MR; Skorokhod A; Gransheier D; Weide B; Koch W; Schif B; Enk A; Garbe C; Bauer J
    PLoS One; 2017; 12(11):e0188602. PubMed ID: 29176861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil.
    Armengot-Carbó M; Nagore E; García-Casado Z; Botella-Estrada R
    J Am Acad Dermatol; 2018 May; 78(5):920-926.e4. PubMed ID: 29307636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
    Lee PJ; Dennis K; Madan R; Fan F
    Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
    Bruno W; Martinuzzi C; Andreotti V; Pastorino L; Spagnolo F; Dalmasso B; Cabiddu F; Gualco M; Ballestrero A; Bianchi-Scarrà G; Queirolo P; Grillo F; Mastracci L; Ghiorzo P;
    Oncotarget; 2017 Jan; 8(5):8069-8082. PubMed ID: 28039443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.